Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634027 | 0.87 | KMT2A (0.58) | KMT2ACASP3TLR2EPHX2MDM4 | |
| SCHEMBL7743458 | 0.80 | KMT2A (0.57) | KMT2ACASP3TLR2EPHX2 | |
| SCHEMBL12761610 | 0.79 | KMT2A (0.59) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL12878333 | 0.79 | KMT2A (0.61) | KMT2ACASP3TLR2EPHX2 | |
| SCHEMBL14008332 | 0.79 | KMT2A (0.64) | KMT2ACASP3TLR2EPHX2 | |
| SCHEMBL9906753 | 0.78 | KMT2A (0.58) | KMT2ATLR2EPHX2 | |
| SCHEMBL12256997 | 0.78 | KMT2A (0.58) | KMT2ACASP3TLR2EPHX2MDM4 | |
| SCHEMBL14765353 | 0.78 | KMT2A (0.53) | KMT2ACASP3TLR2EPHX2CXCR2 | |
| SCHEMBL31546963 | 0.78 | KMT2A (0.57) | KMT2ACASP3TLR2EPHX2MDM4 | |
| SCHEMBL17089903 | 0.78 | KMT2A (0.62) | KMT2ACASP3EPHX2CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007096703-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-08-30 | — | — | WO | disclosed |